This study is investigating Idiopathic CD4 Lymphocytopenia (ICL), a rare condition where your body has consistently low levels of CD4 T cells (a type of immune cell) without a clear cause like HIV. The goal is to understand how these immune cells develop and move within the body. Researchers will give participants two medications, Filgrastim and Plerixafor, to help release special stem cells (CD34+ hematopoietic progenitor cells) from their bone marrow into their bloodstream. These cells will then be collected through a process called apheresis and used in laboratory studies involving mice to learn more about ICL. The study aims to enroll 40 participants, including both ICL patients and healthy volunteers, aged 18 to 65 years old. To be eligible as an ICL patient, you must have a documented history of low CD4 T cell counts.

Study design

This is an interventional study with a planned enrollment of 40 participants. It includes both ICL patients and healthy volunteers.

What's involved

You would receive daily subcutaneous injections of Filgrastim for 5 days, followed by an intravenous injection of Plerixafor 11 hours before apheresis to collect cells.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint, investigating thymic development, survival, and trafficking of cells, will be measured throughout the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.